FDA warned www.peacefulmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and injectable semaglutide to U.S. consumers online.
What happened
FDA reviewed the website www.peacefulmeds.com and observed that it offered unapproved and misbranded opioid and benzodiazepine drugs and injectable semaglutide for sale to U.S. consumers. The site marketed tramadol, diazepam, and Ozempic (semaglutide) and offered prescription drugs without requiring a prescription. FDA cited the FD&C Act, saying the products were unapproved new drugs and the labeling lacked adequate directions for use.
What FDA found
Sold tramadol and diazepam as new drugs without FDA-approved applications.
FD&C Act §§ 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]Sold prescription opioid and benzodiazepine drugs with labeling that lacked adequate directions for safe lay use.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]; § 301(a) [21 U.S.C. § 331(a)]Offered prescription drugs, including Ozempic/semaglutide, without requiring a prescription.
FD&C Act § 503(b)(1) [21 U.S.C. § 353(b)(1)]; § 301(k) [21 U.S.C. § 331(k)]
What FDA wants
FDA requests that www.peacefulmeds.com stop offering any unapproved and misbranded drugs for sale to U.S. consumers. The company must notify FDA in writing within 15 working days of the steps taken to correct violations and prevent recurrence.
Who should pay attention
- online pharmacies and websites selling prescription drugs to U.S. consumers
- consumers who buy opioids, benzodiazepines, or semaglutide online
- telehealth, payment, and shipping companies that serve online drug sellers
This is a summary. Read the original letter on fda.gov.